LKB1 mutations were negatively associated with PD-L1 expression in KRAS-mutated NSCLC tumors, whereas gene expression signatures associated with the infiltration of effector T cells and dendritic cells were reduced in LUAD tumors with LKB1 mutations and NRF2 activation [42]. Here, STK11 is linked to non-small cell lung carcinoma.